The reduced risk of colorectal cancer associated with taking aspirin or other NSAIDs may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood. Researchers report finding that higher baseline levels of a novel inflammatory marker indicated increased risk of developing colorectal tumors and predicted who might benefit from taking aspirin or NSAIDs.